Skip to main content
Log in

Visceral leishmaniasis during pregnancy treated with meglumine antimoniate

Viszerale Leishmaniasis in der Schwangerschaft. Behandlung mit Meglumin Antimonat

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Summary

Data on the efficacy and safety of pentavalent antimony in the treatment of visceral leishmaniasis during pregnancy are scanty. A case of visceral leishmaniasis in a 39-year-old woman in the second trimester of pregnancy is reported here. The patient was hospitalized in poor condition with high fever and pancytopenia which had lasted for 6 weeks. A bone marrow aspirate revealed numerous amastigotes and serodiagnosis forLeishmania was positive at a high titer. The patient was successfully treated with meglumine anti-moniate at a daily dose of 850 mg of antimony for 20 days. She delivered at term a healthy female baby who remains in good condition at 18 months of age. Thus a dose of 850 mg of antimony, which is lower than that presently recommended, seems to be effective and non toxic to the fetus when administered at the second trimester of pregnancy.

Zusammenfassung

Zur Behandlung der Leishmaniasis mit pentavalenten Antimon in der Schwangerschaft liegen nur spärliche Daten vor. Bei einer 39 Jahre alten Frau trat im zweiten Schwangerschaftstrimester eine viszerale Leishmaniasis auf. Die Patientin wurde in schlechtem Zustand mit hohem Fieber und Panzytopenie, die schon über 6 Wochen bestanden hatten, stationär aufgenommen. Im Knochenmarkpunktat fanden sich zahlreiche Amastigoten, die Serodiagnose war hochtitrig-positiv fürLeishmania. Die Patientin wurde erfolgreich mit Meglumin Antimonat mit einer täglichen Dosis von 850 mg Antimon behandelt. Diese Dosis liegt unterhalb der derzeit empfohlenen Dosis, doch scheint sie wirksam und nicht fetotoxisch zu sein, wenn sie im zweiten Schwangerschaftstrimester verabreicht wird.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Berman, J. D. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10 (1988) 560–586.

    Google Scholar 

  2. Rosenblatt, J. E. Symposium on antimicrobial agents. Antiparasitic agents. Mayo Clin. Proc. 67 (1992) 276–287.

    Google Scholar 

  3. Olliaro, P. L., Bryceson, A. D. M. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitology Today 9 (1993) 323–328.

    Google Scholar 

  4. Massip, P., Goutner, Ch., Dupic, Y., Navarrot, P. Kala-Azar chez la femme enceinte. Presse Méd. 20 (1986) 95.

    Google Scholar 

  5. Nyakundi, P. M., Muigai, R., Were, J. B. O., Oster, C. N., Gachihi, G. S., Kirigi, G. Congenital visceral leishmaniasis: case report. Trans. R. Soc. Trop. Med. Hyg. 82 (1988) 564.

    Google Scholar 

  6. Yadav, T. P., Gupta, H., Satteya, U., Kumar, R., Mittal, V. Congenital kala-azar. Ann. Trop. Med. Parasitol. 83 (1989) 535–537.

    Google Scholar 

  7. Kaplanski, G., Farnarier, C., Durand, J., Soubeyrand, J., Bongrand, P., Kaplanski, S. Leishmaniasis acquired in Belgium. Lancet 338 (1991) 885.

    Google Scholar 

  8. Eltoum, I. A., Zijlstra, E. E., Ali, M. S., Ghalib, H. W., Satti, M. M. H., Eltoum, B., El-Assan, A. M. Congenital kala-azar and leishmaniasis in the placenta. Am. J. Trop. Med. Hyg. 46 (1992) 57–62.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Utili, R., Rambaldi, A., Tripodi, M.F. et al. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate. Infection 23, 182–183 (1995). https://doi.org/10.1007/BF01793862

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01793862

Keywords

Navigation